Travere Therapeutics Inc (NASDAQ:TVTX) price on Wednesday, February 05, rose 0.52% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $21.21.
A look at the stock’s price movement, the close in the last trading session was $21.10, moving within a range at $20.6731 and $21.86. The beta value (5-Year monthly) was 0.7. Turning to its 52-week performance, $21.56 and $5.12 were the 52-week high and 52-week low respectively. Overall, TVTX moved 12.46% over the past month.
Travere Therapeutics Inc’s market cap currently stands at around $1.85 billion, with investors looking forward to this quarter’s earnings report slated for in March.
Analysts have a consensus estimate of 72.63M for the company’s revenue for the quarter, with a low and high estimate of 63.6M and 83M respectively. The average forecast suggests up to a 61.18% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 231.13M, representing a 59.14% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that TVTX is a 100% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
8 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 8 recommend TVTX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
TVTX’s current price about 8.08% and 12.96% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 61.98, while 7-day volatility ratio is 4.98% and 5.93% in the 30-day chart. Further, Travere Therapeutics Inc (TVTX) has a beta value of 0.76, and an average true range (ATR) of 1.08. Analysts have given the company’s stock an average 52-week price target of $21.5, forecast between a low of $12 and high of $33. Looking at the price targets, the low is 43.42% off current price level while to achieve the yearly target high, price needs to move -55.59%. Nonetheless, investors will most likely welcome a -1.37% jump to $21.5 which is the analysts’ median price.
If we refocus on Travere Therapeutics Inc (NASDAQ:TVTX), historical trading data shows that trading volumes averaged 1.28 over the past 10 days and 1.28 million over the past 3 months. The company’s latest data on shares outstanding shows there are 87.03 million shares.
The 1.31% of Travere Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 98.02% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 9.58 million on 2025-01-15, giving us a short ratio of 7.3. The data shows that as of 2025-01-15 short interest in Travere Therapeutics Inc (TVTX) stood at 1218.9999 of shares outstanding, with shares short rising to 7.41 million registered in 2024-12-13. Current price change has pushed the stock 21.76% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the TVTX stock continues to rise going into the next quarter.
